No-Gos bei Medikamentenkombis

 

 

Literaturnachweise

1.
Cascorbi I: Arzneimittelinteraktionen. Prinzipien, Beispiele und klinische Folgen. Dtsch Arztebl, 2012; 109 (44–34): 546–56.

2.
Tampi RR, Balderas M, Carter KV, et al.: Citalopram, QTc Prolongation, and Torsades de Pointes. Psychosomatics 2015; 56 (1): 36–43.

3.
Lundbeck GmbH. Rote Hand Brief: Zusammenhang von CIPRAMIL (Citalopramhydrobromid/ Citalopram-hydrochlorid) mit dosisabhängiger QT-Intervall-Verlängerung. 2011; (4089127861): 2–4.

4.
Lundbeck GmbH. Rote Hand Brief: Zusammenhang von Escitalopram (Cipralex) mit dosisabhängiger QT-Intervall-Verlängerung. 2011; (4089127861): 1–3.

5.
Grandt D, Lappe V: Arzneimittelreport 2018 Schriftenreihe Zur Gesundheitsanalyse. 2018.

6.
Zeltser D, Justo D, Halkin A, et al.: Torsade de Pointes Due to Noncardiac Drugs. Medicine (Baltimore) 2003; 82 (4): 282–90.

7.
Pollock BG: Citalopram: a comprehensive review. Expert Opin Pharmacother 2001; 2 (4): 681–98.

8.
Roden DM : Drug-Induced Prolongation of the QT Interval. NEJM 2004; 350 (10): 1013–22.

9.
Yusuf S, Teo KK, Pogue J, et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. NEJM 2008; 358:1547–59.

10.
Parving HH, Brenner BM, McMurray JJ, et al.: Baseline characteristics in the Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 2012; 13: 387–93.

11.
Krüger B, Benck U, Singer T, Krämer B: Nierenfunktionsstörungen durch Medikamente. DMW 2012; 137: 1873–7.

12.
Henrich WL, Agodoa LE, Barrett B, et al.: Analgesics and the kidney: Summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc Committe of the National Kidney Foundation. Am J Kidney Dis 1996; 27: 162–5.

13.
Ungprasert P, Cheungpasitporn W, Crowson CS, et al.: Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and metaanalysis of observational studies. Eur J
Intern Med 2015; 26: 285–91.

14.
Dreischulte T, Morales DR, Bell S, et al.: Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. Kidney Int 2015; 88: 396–403.

15.
Lapi F, Azoulay L, Yin H, et al.: Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 2013; 346: e8525.

16.
Loboz KK, Shenfield GM: Drug combinations and impaired renal function – the ‘triple whammy’. Br J Clin Pharmacol 2005; 59:239–43.

17.
Gutthann SP, Rodríguez LAG, Raiford DS, et al.: Nonsteroidal Anti-inflammatory Drugs and the Risk of Hospitalization for Acute Renal Failure. Arch Intern Med 1996; 156: 2433–9.

18.
Fournier JP, Lapeyre-Mestre M, Sommet A, et al.: Laboratory Monitoring of Patients Treated with Antihypertensive Drugs and Newly Exposed to Non Steroidal Anti-Inflammatory Drugs: A Cohort Study. Burdmann EA (Hrsg.): PLoS ONE 2012; 7: e34187.

19.
Grandt D, Lappe V: Arzneimittelreport 2018 Schriftenreihe zur Gesundheitsanalyse. 2018.

20.
Kern WV: Antibiotika und antibakterielle Chemotherapeutika. In: Schwabe U, Paffrath D, Ludwig WD, Klauber J, editors. Arzneiverordnungs-Report 2019. Berlin, Heidelberg: Springer Berlin Heidelberg; 2019: 435–59.

21.
Hallberg P, Marten L, Wadelius M: Possible fluconazole-fentanyl interaction-a case report. Eur J Clin Pharmacol. 2006; 62 (6): 491–2.

22.
Horton R, Barber C: Opioid-induced respiratory depression resulting from transdermaln fentanyl-clarithromycin drug interaction in a patient with advanced COPD. J Pain Symptom Manage 2009; 37 (6): e2–5.

23.
Mercadante S, Villari P, Ferrera P: Itraconazole-fentanyl interaction in a cancer patient. J Pain Symptom Manage 2002; 24 (3): 284–6.

24.
Cronnolly B, Pegrum H: Fentanyl-clarithromycin interaction. BMJ Case Rep. 2012; 2012.

25.
Liukas A, Hagelberg NM, Kuusniemi K, et al.: Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers. J Clin Psychopharmacol. 2011; 31 (3): 302–8.

26.
Tempelhoff R, Modica PA, Spitznagel EL, Jr: Anticonvulsant therapy increases fentanyl requirements during anaesthesia for craniotomy. Can J Anaesth 1990; 37 (3): 327–32.

27.
Niwa T, Imagawa Y, Yamazaki H: Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. Current drug metabolism 2014; 15 (7): 651–79.

28.
AWMF: S2k-Leitlinie: Tuberkulose im Erwachsenenalter. 2017. www.awmf. org/upload /tx_szleitlinien/020–019l_S2k_ Tuberkulose_im_Erwachsenen-alter_2017–11.pdf.

29.
WHO: Guidelines for treatment of drug-susceptible tuberculosis and patient care. 2017 update. www.who.int/tb/publications/2017/dstb_guidance_2017/en/.

30.
Hoiby N, Bjarnsholt T, Moser C, et al.: ESCMID Guideline for the diagnosis and treatment of biofilm infections 2014. CMI 2015; 21 (S1): S1–25.

31.
Eljaaly K, Alshehri S, Bhattacharjee S, et al.: Contraindicated drug-drug interactions associated with oral antimicrobial agents prescribed in the ambulatory care setting in the United States. CMI 2019; 25: 620–22.

32.
Finch CK, Chrisman CR, Baciewicz A, et al.: Rifampin and Rifabutin Drug Interactions – An Update. JAMA 2002; 162: 985–92.

33.
Kim KY, Epplen K, Foruhari F, et al.: Update on the interaction of rifampicin and warfarin. Prog Cardiovasc Nurs 2007; 22 (2): 97–100.

34.
Mizera L, Geisler T, Mörike K, et al.: Problems in anticoagulation of a patient with antibiotic treatment for endocarditis: interaction of rifampicin and vitamin K antagonists. BMJ Case Reports 2018: bcr2016215155.

35.
Rogers KC, Neu DW, Jaeger MC, et al.: An underappreciated and prolonged drug interaction leads to ineffective anticoagulation. South Med J 2019; 112 (2): 125–9.

36.
Narum S, Westergren T, Klemp M: Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMC Open 2014; 4: e004587.

37.
Piper JM, Ray WA, Daugherty JR, Griffin MR et al.: Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735–40.

38.
Fischbach WPM, Lynen Jansen P, Bolten W, et al.: S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit. Z Gastroenterol 2016; 53: 327–63.

39.
Koop H, Labenz J: Ulkuskrankheit – Update. Gastroenterol up2date 2016; 12: 193–206.

40.
Scarpingnato C, Gatta L, Zullo A, et al.: Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Med 2016; 14: 179.

41.
Masclee GM, Valkhoff VE, Coloma PM, et al.: Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 2014; 147: 784–92.

42.
Rodriguez LAG, Hernandez-Diaz S: The risk of upper gastrointestinal complications associated with anti-inflammatory drugs, corticosteroids, acetaminophen, and combinations of these agents. Arthritis Res 2001; 3: 96–101.

43.
Weil J, Langman MJS, Wainwright P, et al.: Peptic ulcer bleeding: accessory risk factors and interactions with nonsteroidal anti-inflammatory drugs. Gut 2000; 46: 27–31.

44.
Hasenfuß G, Fölsch UR: Klug entscheiden: Rationale, Umsetzung, Evaluation. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen ZEFQ; Volume 129, Dezember 2017, 37–40

45.
Hasenfuß G, Märker-Herrmann E, Halle M, et al.: Gegen Unter- und Überversorgung. Dtsch Arztebl 2016; 113 (13) (Sonderdruck).

46.
Wilcock A, Thomas J, Frisby J, et al.: Potential for drug interactions involving cytochrome P450 in patients attending palliative day care centres: a multicentre audit. British Journal of Clinical Pharmacology 2005; 60 (3): 326–9.

47.
Kotlinska-Lemieszek A, Paulsen O, Kaasa S, et al.: Polypharmacy in Patients With Advanced Cancer and Pain: A European Cross-sectional Study of 2282 Patients.  Pain Symptom Manage 2014; 48 (6): 1145–59.

48.
YouScript [Internet]. 2020 [cited 22 July 2020]. Available from: www.youscript.com.

Wir verwenden Cookies auf Ihrem Browser, um die Funktionalität unserer Webseite zu optimieren und den Besuchern personalisierte Werbung anbieten zu können. Bitte bestätigen Sie die Auswahl der Cookies um direkt zu der Webseite zu gelangen. Weitere Informationen finden Sie unter Datenschutz. Dort können Sie auch jederzeit Ihre Cookie-Einstellungen ändern.

Infos
Infos
Mehr Info